{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:20:50Z","timestamp":1789737650925,"version":"4.0.1"},"reference-count":31,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2014,11,21]]},"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background and aim<\/jats:title>\n                    <jats:p>Although Non-steroidal anti-inflammatory drugs reduce colorectal adenoma burden in familial adenomatous polyposis (FAP), the utility of combining chemopreventive agents in FAP is not known. We conducted a randomised trial of celecoxib (CXB) versus CXB+diflouromethylornithine (DFMO) to determine the synergistic effect, if any.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The primary endpoint was % change in adenoma count in a defined field. Secondary endpoints were adenoma burden (weighted by adenoma diameter) and video review of entire colon\/rectal segments. Adverse event (AEs) were monitored by National Cancer Institution toxicity criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>112 subjects were randomised: 60 men and 52 women at a mean age of 38\u2005years. For the 89 patients who had landmark-matched polyp counts available at baseline and 6\u2005months, the mean % change in adenoma count over the 6\u2005months of trial was \u221213.0% for CXB+DFMO and \u22121.0% for CXB (p=0.69). Mean % change in adenoma burden was \u221240% (CXB+DFMO) vs \u221227% (CXB) (p=0.13). Video-based global polyp change was \u22120.80 for CXB+DFMO vs \u22120.33 for CXB (p=0.03). Fatigue was the only significant AE, worse on the CXB arm (p=0.02).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CXB combined with DFMO yielded moderate synergy according to a video-based global assessment. No significant difference in adenoma count, the primary endpoint, was seen between the two study arms. No evidence of DFMO-related ototoxicity was seen. There were no adverse cardiovascular outcomes in either trial arm and no significant increase in AEs in the CXB+DFMO arm of the trial. Differences in outcomes between primary and secondary endpoints may relate to sensitivity of the endpoint measures themselves.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ClinicalTrials.gov number N01-CN95040.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2014-307235","type":"journal-article","created":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T10:35:23Z","timestamp":1426847723000},"page":"286-295","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":97,"title":["An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis"],"prefix":"10.1136","volume":"65","author":[{"given":"Patrick M","family":"Lynch","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Nutrition, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A","family":"Burke","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Phillips","sequence":"additional","affiliation":[{"name":"The Polyposis Registry, St. Mark's Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Morris","sequence":"additional","affiliation":[{"name":"Division of Quantitative Sciences, Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Slack","sequence":"additional","affiliation":[{"name":"Division of Quantitative Sciences, Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Quantitative Sciences, Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherri","family":"Patterson","sequence":"additional","affiliation":[{"name":"Department of Cancer Prevention and Pop Science, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank A","family":"Sinicrope","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A","family":"Rodriguez-Bigas","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Half","sequence":"additional","affiliation":[{"name":"Gatroenterology Department, Rambam Medical Center, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Bulow","sequence":"additional","affiliation":[{"name":"Hvidore Hospital, Denmark, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Latchford","sequence":"additional","affiliation":[{"name":"The Polyposis Registry, St. Mark's Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Clark","sequence":"additional","affiliation":[{"name":"The Polyposis Registry, St. Mark's Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Nutrition, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Malone","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Nutrition, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hennie","family":"Hasson","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Richmond","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, The National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Hawk","sequence":"additional","affiliation":[{"name":"Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,3,19]]},"reference":[{"key":"2025120523184331000_65.2.286.1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1651562"},{"key":"2025120523184331000_65.2.286.2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.136127"},{"key":"2025120523184331000_65.2.286.3","first-page":"92","article-title":"Linkage of a variant or attenuated form of adenomatous polyposis coli to the adenomatous polyposis coli (APC) locus","volume":"51","author":"Spirio","year":"1992","journal-title":"Am J Hum Genet"},{"issue":"(3 Pt 1)","key":"2025120523184331000_65.2.286.4","first-page":"G393","article-title":"Prostaglandin endoperoxide synthase: why two isoforms?","volume":"270","author":"Williams","year":"1996","journal-title":"Am J Physiol"},{"key":"2025120523184331000_65.2.286.5","doi-asserted-by":"publisher","DOI":"10.1007\/s002619900127"},{"key":"2025120523184331000_65.2.286.6","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/0016-5085(94)90246-1","article-title":"Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas","volume":"107","author":"Eberhart","year":"1994","journal-title":"Gastroenterology"},{"key":"2025120523184331000_65.2.286.7","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1055-9965.920.13.6","article-title":"Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients","volume":"13","author":"Sinicrope","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025120523184331000_65.2.286.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70330-0"},{"key":"2025120523184331000_65.2.286.9","first-page":"2562","article-title":"Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet","volume":"50","author":"Reddy","year":"1990","journal-title":"Cancer Res"},{"key":"2025120523184331000_65.2.286.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81988-1"},{"key":"2025120523184331000_65.2.286.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006293422603"},{"key":"2025120523184331000_65.2.286.12","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026130623186"},{"key":"2025120523184331000_65.2.286.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061355"},{"key":"2025120523184331000_65.2.286.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061652"},{"key":"2025120523184331000_65.2.286.15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.08.079"},{"key":"2025120523184331000_65.2.286.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050405"},{"key":"2025120523184331000_65.2.286.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050493"},{"key":"2025120523184331000_65.2.286.18","first-page":"945","article-title":"Development of difluoromethylornithine (DFMO) as a chemoprevention agent","volume":"5","author":"Meyskens","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2025120523184331000_65.2.286.19","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.4269\/ajtmh.1986.35.1153","article-title":"Inhibition of polyamine biosynthesis by alpha-difluoromethylornithine in African trypanosomes and Pneumocystis carinii as a basis of chemotherapy: biochemical and clinical aspects","volume":"35","author":"McCann","year":"1986","journal-title":"Am J Trop Med Hyg"},{"key":"2025120523184331000_65.2.286.20","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1016\/S0021-9258(18)38070-0","article-title":"Control of ornithine decarboxylase activity in alpha-difluoromethylornithine-resistant L1210 cells by polyamines and synthetic analogues","volume":"263","author":"Pegg","year":"1988","journal-title":"J Biol Chem"},{"key":"2025120523184331000_65.2.286.21","first-page":"2545","article-title":"Inhibition of ornithine decarboxylase with 2-difluoromethylornithine: reduced incidence of dimethylhydrazine-induced colon tumors in mice","volume":"43","author":"Kingsnorth","year":"1983","journal-title":"Cancer Res"},{"key":"2025120523184331000_65.2.286.22","first-page":"5793","article-title":"Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment","volume":"49","author":"Tempero","year":"1989","journal-title":"Cancer Res"},{"key":"2025120523184331000_65.2.286.23","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/20.3.425"},{"key":"2025120523184331000_65.2.286.24","first-page":"4528","article-title":"Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination","volume":"51","author":"Rao","year":"1991","journal-title":"Cancer Res"},{"key":"2025120523184331000_65.2.286.25","first-page":"989","article-title":"A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer","volume":"7","author":"Love","year":"1998","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025120523184331000_65.2.286.26","first-page":"303","article-title":"Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia","volume":"4","author":"Mitchell","year":"1998","journal-title":"Clin Cancer Res"},{"key":"2025120523184331000_65.2.286.27","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.16.1212"},{"key":"2025120523184331000_65.2.286.28","first-page":"1864","article-title":"Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos","volume":"60","author":"Jacoby","year":"2000","journal-title":"Cancer Res"},{"key":"2025120523184331000_65.2.286.29","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-08-0042"},{"key":"2025120523184331000_65.2.286.30","doi-asserted-by":"publisher","DOI":"10.2307\/2530245"},{"key":"2025120523184331000_65.2.286.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2012.11.038"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2014-307235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T07:18:49Z","timestamp":1765005529000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2014-307235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,19]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,1,6]]},"published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1136\/gutjnl-2014-307235"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2014-307235","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,19]]}}}